Joanne Barnes Weidhaas

List of Publications by Year
in descending order

91	7,545	117453	54797
papers	citations	34 h-index	84 g-index

93	93	93	11114
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer. Journal of Clinical Oncology, 2006, 24, 5652-5657.	0.8	956
2	Systemic Delivery of Tumor Suppressor microRNA Mimics Using a Neutral Lipid Emulsion Inhibits Lung Tumors in Mice. Molecular Therapy, 2011, 19, 1116-1122.	3.7	610
3	A SNP in a let-7 microRNA Complementary Site in the KRAS 3â€² Untranslated Region Increases Nonâ€“Small Cell Lung Cancer Risk. Cancer Research, 2008, 68, 8535-8540.	0.4	609
4	Thelet-7microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle, 2008, 7, 759-764.	1.3	588
5	Regression of murine lung tumors by the let-7 microRNA. Oncogene, 2010, 29, 1580-1587.	2.6	465
6	Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1695-704.	3.3	439
7	MicroRNAs as Potential Agents to Alter Resistance to Cytotoxic Anticancer Therapy. Cancer Research, 2007, 67, 11111-11116.	0.4	369
8	microRNA miR-196a-2 and Breast Cancer: A Genetic and Epigenetic Association Study and Functional Analysis. Cancer Research, 2009, 69, 5970-5977.	0.4	325
9	Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 2010, 42, 880-884.	9.4	235
10	The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene, 2009, 28, 2419-2424.	2.6	221
11	MicroRNA in Cancer Prognosis. New England Journal of Medicine, 2008, 359, 2720-2722.	13.9	161
12	A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research, 2010, 70, 6509-6515.	0.4	135
13	A 3â€²-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncology, The, 2011, 12, 377-386.	5.1	130
14	MicroRNAs: tools for cancer diagnostics. Gut, 2009, 58, 1546-1554.	6.1	110
15	Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Cancer Biology and Therapy, 2011, 12, 908-914.	1.5	108
16	A Let-7 MicroRNA SNP in the KRAS 3â€²UTR Is Prognostic in Early-Stage Colorectal Cancer. Clinical Cancer Research, 2011, 17, 7723-7731.	3.2	106
17	MicroRNA signatures differentiate melanoma subtypes. Cell Cycle, 2011, 10, 1845-1852.	1.3	98
18	Characteristics and Outcomes of Breast Cancer in Women With and Without a History of Radiation for Hodgkin's Lymphoma: A Multi-Institutional, Matched Cohort Study. Journal of Clinical Oncology, 2011, 29, 2466-2473.	0.8	91

#	Article	IF	Citations
19	MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecologic Oncology, 2010, 118, 251-257.	0.6	88
20	miRNA modulation of the cellular stress response. Future Oncology, 2008, 4, 289-298.	1.1	86
21	A polymorphism in a letâ€7 microRNA binding site of KRAS in women with endometriosis. EMBO Molecular Medicine, 2012, 4, 206-217.	3.3	83
22	SNPing cancer in the bud: MicroRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. , 2013, 137, 55-63.		83
23	MicroRNAs as a potential magic bullet in cancer. Future Oncology, 2006, 2, 73-82.	1.1	72
24	A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene, 2012, 31, 4559-4566.	2.6	71
25	Cancer microRNAs: From subtype profiling to predictors of response to therapy. Trends in Molecular Medicine, 2011, 17, 235-243.	3.5	68
26	MicroRNA binding site polymorphisms as biomarkers of cancer risk. Expert Review of Molecular Diagnostics, 2010, 10, 817-829.	1.5	65
27	A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma. Clinical Cancer Research, 2020, 26, 1829-1836.	3.2	63
28	miR-34 activity is modulated through 5â€²-end phosphorylation in response to DNA damage. Nature Communications, 2016, 7, 10954.	5.8	58
29	A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy. Clinical Cancer Research, 2014, 20, 4499-4510.	3.2	55
30	The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer. JAMA Oncology, 2017, 3, 483.	3.4	51
31	Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. International Journal of Radiation Oncology Biology Physics, 2018, 101, 274-284.	0.4	50
32	Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. International Journal of Molecular Epidemiology and Genetics, 2011, 2, 9-18.	0.4	42
33	Extensive sequence variation in the 3â€² untranslated region of theKRASgene in lung and ovarian cancer cases. Cell Cycle, 2014, 13, 1030-1040.	1.3	39
34	A Prospective, Multicenter Study of Complementary/Alternative Medicine (CAM) Utilization During Definitive Radiation for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 40-46.	0.4	37
35	RareBRCA1haplotypes including 3â€™UTR SNPs associated with breast cancer risk. Cell Cycle, 2011, 10, 90-99.	1.3	36
36	Prevalence of the variant allele rs61764370 T>G in the 3â€²UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Research and Treatment, 2011, 128, 79-84.	1.1	35

#	Article	IF	Citations
37	Preoperative Chemotherapy Decreases the Need for Re-Excision of Breast Cancers Between 2 and 4Âcm Diameter. Annals of Surgical Oncology, 2009, 16, 697-702.	0.7	34
38	A Variant in a MicroRNA complementary site in the 3â€² UTR of the KIT oncogene increases risk of acral melanoma. Oncogene, 2011, 30, 1542-1550.	2.6	33
39	SNPs in MicroRNA Binding Sites as Prognostic and Predictive Cancer Biomarkers. Critical Reviews in Oncogenesis, 2013, 18, 327-340.	0.2	32
40	Postmastectomy radiation therapy for lymph nodeâ€negative, locally advanced breast cancer after modified radical mastectomy. Cancer, 2008, 113, 38-47.	2.0	31
41	The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer. PLoS ONE, 2012, 7, e37891.	1.1	30
42	The patient's perspective on breast radiotherapy: Initial fears and expectations versus reality. Cancer, 2018, 124, 1673-1681.	2.0	30
43	Using microRNAs to understand cancer biology. Lancet Oncology, The, 2010, 11, 106-107.	5.1	29
44	Functional micro<scp>RNA</scp> binding site variants. Molecular Oncology, 2019, 13, 4-8.	2.1	28
45	Tumor-associated mutations in a conserved structural motif alter physical and biochemical properties of human RAD51 recombinase. Nucleic Acids Research, 2015, 43, 1098-1111.	6.5	27
46	Current Status and Recommendations for the Future ofÂResearch, Teaching, and Testing in the Biological Sciences of Radiation Oncology: Report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, Executive Summary. International Journal of Radiation Oncology Biology Physics, 2014, 88, 11-17.	0.4	26
47	A Conserved RAS/Mitogen-Activated Protein Kinase Pathway Regulates DNA Damageâ€“Induced Cell Death Postirradiation in Radelegans. Cancer Research, 2006, 66, 10434-10438.	0.4	24
48	Targeted resequencing of the microRNAome and 3â€²UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer. Oncogene, 2015, 34, 2125-2137.	2.6	24
49	KRAS alleles: The LCS6 3â€²UTR variant and KRAS coding sequence mutations in the NCI-60 panel. Cell Cycle, 2012, 11, 361-366.	1.3	23
50	Breast Sentinel Lymph Node Dissection Before Preoperative Chemotherapy. Archives of Surgery, 2008, 143, 692.	2.3	22
51	Regulation of autophagy, NF-ÎºB signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells. Science Signaling, 2017, 10, .	1.6	21
52	Changes in Gene Expression Predicting Local Control in Cervical Cancer: Results from Radiation Therapy Oncology Group 0128. Clinical Cancer Research, 2009, 15, 4199-4206.	3.2	20
53	Enhancing Career Paths for Tomorrow's Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2019, 105, 52-63.	0.4	20
54	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. European Urology, 2020, 78, 327-332.	0.9	18

#	Article	IF	Citations
55	MicroRNA Binding-Site Polymorphisms as Potential Biomarkers of Cancer Risk. Molecular Diagnosis and Therapy, 2010, 14, 335-342.	1.6	17
56	The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905. PLoS ONE, 2014, 9, e94167.	1.1	17
57	COX-2 Expression and Survival in Patients With Locally Advanced Cervical Cancer Treated With Chemoradiotherapy and Celecoxib: A Quantitative Immunohistochemical Analysis of RTOG C0128. International Journal of Gynecological Cancer, 2013, 23, 176-183.	1.2	16
58	Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy. , 2022, 10, e003625.		16
59	Ribonucleotide Reductase Expression in Cervical Cancer. International Journal of Gynecological Cancer, 2013, 23, 615-621.	1.2	15
60	A germline mutation in the BRCA13â€™UTR predicts Stage IV breast cancer. BMC Cancer, 2014, 14, 421.	1.1	14
61	Breast Cancer and miR-SNPs: The Importance of miR Germ-Line Genetics. Non-coding RNA, 2019, 5, 27.	1.3	14
62	Estrogen Drives Cellular Transformation and Mutagenesis in Cells Expressing the Breast Cancerâ€“Associated R438W DNA Polymerase Lambda Protein. Molecular Cancer Research, 2016, 14, 1068-1077.	1.5	12
63	Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. Cell Cycle, 2015, 14, 2091-2099.	1.3	11
64	MicroRNAs and Cancer. , 2017, , 277-286.		11
65	MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. Human Pathology, 2018, 76, 133-140.	1.1	11
66	The Holman Research Pathway in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2011, 80, 321-323.	0.4	10
67	miRNAs in the spotlight: Making 'silent' mutations speak up. Nature Medicine, 2011, 17, 934-935.	15.2	8
68	Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. Radiotherapy and Oncology, 2022, 167, 226-232.	0.3	7
69	Radiation Therapy Oncology Group Gynecologic Oncology Working Group: Comprehensive Results. International Journal of Gynecological Cancer, 2014, 24, 956-962.	1.2	6
70	The KRAS-variant and cetuximab response in RTOG 0522.. Journal of Clinical Oncology, 2014, 32, 6000-6000.	0.8	6
71	Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer. Clinical Breast Cancer, 2018, 18, e205-e218.	1.1	5
72	The KRAS-variant and treatment response in BATTLE-1.. Journal of Clinical Oncology, 2014, 32, 8135-8135.	0.8	5

#	Article	IF	Citations
73	Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen Receptor-Positive, Clinically Node-Positive Disease. Annals of Surgical Oncology, 2022, 29, 4716-4724.	0.7	5
74	KRAS rs61764370 in Epithelial Ovarian Cancerâ€“Letter. Clinical Cancer Research, 2011, 17, 6600-6600.	3.2	4
75	A phase II trial of balloon-catheter partial breast brachytherapy optimization in the treatment of stage 0, I, and IIA breast carcinoma. Journal of Radiation Oncology, 2014, 3, 371-378.	0.7	3
76	The KRAS-variant and its impact on normal breast epithelial cell biology. Cell Death and Differentiation, 2019, 26, 2568-2576.	5.0	3
77	Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy. Frontiers in Oncology, 2020, 10, 786.	1.3	3
78	Patient-Reported Outcomes and Cosmesis in a Feasibility Study of 4-Dimensional Simulated Image Guided Accelerated Partial Breast Irradiation. Practical Radiation Oncology, 2019, 9, e257-e265.	1.1	2
79	Association of the 3'-untranslated region KRAS-variant with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 6016-6016.	0.8	2
80	Viral Burden and Clearance in Asymptomatic COVID-19 Patients. Open Forum Infectious Diseases, 2022, 9, ofac126.	0.4	2
81	Association between KRAS rs61764370 and triple-negative breast cancerâ€”a false positive? â€“ Authors' reply. Lancet Oncology, The, 2011, 12, 724.	5.1	1
82	The Non-Coding RNA Journal Club: Highlights on Recent Papersâ€”4. Non-coding RNA, 2016, 2, 9.	1.3	1
83	Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer. Breast Cancer Research and Treatment, 2017, 166, 145-156.	1.1	1
84	Lack of an Association between a Polymorphism in the KRAS 3â€² Untranslated Region (rs61764370) and Endometriosis in a Large European Case-Control Study. Gynecologic and Obstetric Investigation, 2019, 84, 575-582.	0.7	1
85	Identifying MicroRNA Pathway Variants as Biomarkers of Patient Selection for Immune Therapy. Methods in Molecular Biology, 2020, 2055, 203-212.	0.4	1
86	FDG-PET/CT for planning of radiation therapy. , 0, , 10-23.		1
87	KRAS-LCS6 Genotype as a Prognostic Marker in Early-Stage CRCâ€“Response. Clinical Cancer Research, 2012, 18, 3489-3489.	3.2	0
88	Business Development from Research, Entrepreneurship Within Academic Medicine. , 2021, , 343-359.		0
89	Genomic biomarkers to predict outcome in Gleason Score 9-10 disease.. Journal of Clinical Oncology, 2019, 37, 44-44.	0.8	0
90	A germline microRNA-based biomarker signature of immune-associated toxicity to anti-PD1/PDL1 therapy.. Journal of Clinical Oncology, 2019, 37, 96-96.	0.8	0

#	Article	IF	Citations
91	ASO Visual Abstract: EpigeneticÂSignaturesÂPredictÂPathologic NodalÂStage inÂBreast Cancer Patients withÂEstrogen-Receptor-Positive,ÂClinically Node-Positive Disease. Annals of Surgical Oncology, 2022, , .	0.7	0